Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Neuvana is a private U.S. health and wellness technology company focused on non-invasive vagus nerve stimulation. Its core commercial product, Xen, is a consumer device that delivers transcutaneous auricular vagus nerve stimulation through conductive earbuds paired with a mobile app to support calm, sleep, focus, and stress reduction. The company positions itself at the intersection of neuroscience, consumer wellness, and connected hardware rather than as a traditional therapeutics biotech or pharmaceutical developer. Neuvana appears to market directly to consumers and emphasizes science-backed, non-prescription nervous-system regulation tools. Based on publicly available information, its business is centered on commercial neuromodulation devices and related accessories rather than a drug pipeline.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Neuvana.